BioSpace News Archive

Gravyty and iWave, leaders in fundraising enablement and efficiency, have expanded their strategic partnership.

Divurgent, a nationally recognized healthcare IT consulting firm, announced that the firm has brought on Bill Bottomley and Mary Beth Seaman as part of their growing team of Client Services.

Tivic Health™ Systems today announced the expansion of its executive team with the appointments of Subinoy Das, MD as Chief Medical Officer and Michael Nketiah as Vice President of Quality and Regulatory Affairs

Hospital executives have closed or are threatening to eliminate essential services from Greenfield to Taunton, prompting patients, nurses and advocates to push for legislation that will strengthen the existing hospital closure law, shine a light on hospital profits and offshore tax havens, and limit excessive CEO pay.

EVERSANA,™ the leading independent provider of commercial services to the life science industry, today announced the acquisition of Alamo Pharma Services®, Inc. and BexR Logistix®, LLC Telesales from Mission Pharmacal® Company.

Proximo Medical today announced that it has been selected as the marketing and commercial partner for Walk Vascular, an innovative medical device company that has developed JETi, a novel Peripheral Thrombectomy Catheter.

Synaffix B.V., a Dutch biotechnology company focused on the advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that ADC Therapeutics has triggered a third target-specific license under its existing Commercial License Agreement dated October 2016.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it has received clearance from the U.S. Food & Drug Administration

Solidarity HealthShare proudly recognizes May as Mental Health Month—a tradition that began 70 years ago by Mental Health America.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed the second closing and issuance of convertible promissory notes and received the final $650,000 from its convertible debt financing in February.